RU2007119721A - Частицы для лечения легочной инфекции - Google Patents

Частицы для лечения легочной инфекции Download PDF

Info

Publication number
RU2007119721A
RU2007119721A RU2007119721/15A RU2007119721A RU2007119721A RU 2007119721 A RU2007119721 A RU 2007119721A RU 2007119721/15 A RU2007119721/15 A RU 2007119721/15A RU 2007119721 A RU2007119721 A RU 2007119721A RU 2007119721 A RU2007119721 A RU 2007119721A
Authority
RU
Russia
Prior art keywords
composition according
aggregates
composition
respiratory
group
Prior art date
Application number
RU2007119721/15A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид А. ЭДВАРДС (US)
Дэвид А. ЭДВАРДС
Дженнифер ФИГЕЛЬ (US)
Дженнифер ФИГЕЛЬ
Джин САНГ (US)
Джин САНГ
Original Assignee
Президент Энд Феллоуз Оф Гарвард Колледж (Us)
Президент Энд Феллоуз Оф Гарвард Колледж
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Президент Энд Феллоуз Оф Гарвард Колледж (Us), Президент Энд Феллоуз Оф Гарвард Колледж filed Critical Президент Энд Феллоуз Оф Гарвард Колледж (Us)
Publication of RU2007119721A publication Critical patent/RU2007119721A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2007119721/15A 2004-10-29 2005-10-19 Частицы для лечения легочной инфекции RU2007119721A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62373804P 2004-10-29 2004-10-29
US60/623,738 2004-10-29
PCT/US2005/037484 WO2007011396A2 (en) 2004-10-29 2005-10-19 Particles for treatment of pulmonary infection

Publications (1)

Publication Number Publication Date
RU2007119721A true RU2007119721A (ru) 2008-12-10

Family

ID=37667331

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007119721/15A RU2007119721A (ru) 2004-10-29 2005-10-19 Частицы для лечения легочной инфекции

Country Status (11)

Country Link
US (1) US8846607B2 (cg-RX-API-DMAC7.html)
EP (1) EP1809252A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008518007A (cg-RX-API-DMAC7.html)
CN (1) CN101090711A (cg-RX-API-DMAC7.html)
AU (1) AU2005334514B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0517374A (cg-RX-API-DMAC7.html)
CA (1) CA2585859C (cg-RX-API-DMAC7.html)
IL (1) IL182785A0 (cg-RX-API-DMAC7.html)
RU (1) RU2007119721A (cg-RX-API-DMAC7.html)
WO (1) WO2007011396A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200703452B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2399385C1 (ru) * 2009-03-10 2010-09-20 Общество с ограниченной ответственностью "Научно-производственная фирма "НОРД" Способ профилактической обработки животных и птиц

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2987238T3 (es) 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
JP2012524817A (ja) * 2009-04-24 2012-10-18 シェーリング コーポレイション 標的粒子サイズを有する、活性医薬を含む凝集体配合物
US20120076838A1 (en) * 2009-05-27 2012-03-29 Samyang Biopharmaceuticals Corporation Poorly soluble drug containing microsphere with improved bioavailabilty and method of preparing the same
CN102573886A (zh) * 2009-09-17 2012-07-11 相互制药公司 用抗病毒剂治疗哮喘的方法
CN102225058A (zh) * 2011-06-22 2011-10-26 中国药科大学 磷酸奥司他韦吸入粉雾剂及其制备方法
KR20140147891A (ko) * 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
RU2562550C2 (ru) * 2013-12-19 2015-09-10 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных" (ФГБНУ ВНИИБТЖ) Способ специфической профилактики туберкулеза
CN114617959A (zh) 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
WO2018226949A1 (en) 2017-06-08 2018-12-13 Pai Life Sciences Inc. Cpzen compositions and uses
CN109260180A (zh) * 2017-07-17 2019-01-25 北京盈科瑞创新药物研究有限公司 一种盐酸莫西沙星雾化吸入用溶液制剂及其制备方法
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
CN120227451A (zh) 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
EA202190331A1 (ru) * 2018-07-24 2021-06-17 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Композиции терапевтически активных частиц с модифицированной поверхностью, полученные путем ультрабыстрой заморозки
BR112022022243A2 (pt) * 2020-05-01 2022-12-20 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Bloqueadores do canal de proteína e e inibidores de orf3 como agentes anti-covid-19.
WO2021230340A1 (ja) * 2020-05-14 2021-11-18 興和株式会社 新規吸入剤
JPWO2022044582A1 (cg-RX-API-DMAC7.html) * 2020-08-28 2022-03-03
CA3206024A1 (en) * 2021-02-01 2022-08-04 The Global Alliance For Tb Drug Development, Inc. Pretomanid amorphous form
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
CN113907360A (zh) * 2021-07-30 2022-01-11 湖南达侑科技有限公司 植物甾醇磷脂组合物及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) * 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
IT1228459B (it) * 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
JP2930421B2 (ja) * 1994-02-28 1999-08-03 メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤組成物、その製造方法及びその使用方法
DE69535897D1 (de) * 1994-03-07 2009-01-22 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
US5814617A (en) * 1994-10-07 1998-09-29 The United States Of America As Represented By The Secretary Of The Navy Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene
DK0752245T3 (da) 1995-07-05 2002-09-09 Europ Economic Community Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
DE60025019T2 (de) * 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
US6766799B2 (en) * 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
WO2003043586A2 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
WO2004024213A2 (en) * 2002-09-12 2004-03-25 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Aerosolized capreomycin for inhibition of pulmonary tuberculosis
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
NZ541681A (en) * 2003-02-10 2009-02-28 Bayer Healthcare Ag Treatment of bacterial diseases of the respiratory organs by locally applying ciprofloxacin and its salts

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2399385C1 (ru) * 2009-03-10 2010-09-20 Общество с ограниченной ответственностью "Научно-производственная фирма "НОРД" Способ профилактической обработки животных и птиц

Also Published As

Publication number Publication date
WO2007011396A2 (en) 2007-01-25
BRPI0517374A (pt) 2008-10-07
EP1809252A2 (en) 2007-07-25
JP2008518007A (ja) 2008-05-29
ZA200703452B (en) 2008-06-25
US8846607B2 (en) 2014-09-30
US20080213373A1 (en) 2008-09-04
AU2005334514A1 (en) 2007-01-25
CA2585859A1 (en) 2007-01-25
CA2585859C (en) 2012-03-06
IL182785A0 (en) 2007-09-20
WO2007011396A3 (en) 2007-05-03
AU2005334514B2 (en) 2009-11-26
CN101090711A (zh) 2007-12-19

Similar Documents

Publication Publication Date Title
JP2008518007A5 (cg-RX-API-DMAC7.html)
CA2585859A1 (en) Particles for treatment of pulmonary infection
JP2011520911A5 (cg-RX-API-DMAC7.html)
JP2012522009A (ja) 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
JP2012503668A5 (cg-RX-API-DMAC7.html)
WO2017027402A1 (en) Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en) Methods for the treatment of mast cell related disorders with mast cell stabilizers
JP2010285436A5 (cg-RX-API-DMAC7.html)
CN115955965A (zh) 用于治疗、改善或预防微生物感染的制造产品和方法
JP2010270130A5 (cg-RX-API-DMAC7.html)
JP2011173929A (ja) 呼吸器官の細菌性疾患の処置
TW200815003A (en) Treating cystic fibrosis with antibiotics via a swirler delivery
Chaudhary et al. Recent updates in inhalable drug delivery system against various pulmonary diseases: challenges and future perspectives
JP2023524064A (ja) ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法
JP2022527054A5 (cg-RX-API-DMAC7.html)
US20160250142A1 (en) Inhaled aerosolized immuno-chemotherapy for the treatement of mdr tb
JP2011006424A5 (cg-RX-API-DMAC7.html)
Kumar et al. Nanostructure-based pulmonary drug delivery systems for respiratory infections
WO2023141278A3 (en) Composite particle formulations and applications thereof
JP4936320B2 (ja) ナノ粒子用デバイス
WO2022047538A1 (en) System and method for delivery of a therapeutic agent by inhalation
PR et al. Nano Aerogels an Aerosolised Gel Therapy
Athamneh Preparation and Characterization of Nanoporous Micro Particles as Potential Carrier for Pulmonary Drug Delivery using Supercritical Fluid Technology
RU2217159C1 (ru) Раствор для ингаляций фармацевтической композиции глутовент и способ его терапевтического применения
WO2022162635A1 (en) Novel antiviral compositions and their use in therapy and in the treatment of viral infections

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090303

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090303